Literature DB >> 23001251

Gross pathological classification of peripheral cholangiocarcinoma determines the efficacy of hepatectomy.

Chun-Nan Yeh1, Ta-Sen Yeh, Tse-Ching Chen, Yi-Yin Jan, Miin-Fu Chen.   

Abstract

BACKGROUND: Peripheral cholangiocarcinoma (PCC) can be grossly classified as mass-forming (MF), periductal-infiltrating (PI), and intraductal papillary (IP) types. IP-PCC should be distinguished from other types of PCC because patients with IP-PCC have a more favorable prognosis. We hypothesized that gross pathological classification of non-IP-PCC could determine the efficacy of hepatectomy.
METHODS: We retrospectively reviewed 224 histologically proven PCCs (including 172 PCCs from patients having non-IP type tumors) from patients who underwent hepatectomy between 1977 and 2007. Non-IP-PCCs were further classified as MF, MF mixed with PI (MF-PI), and PI for comparison.
RESULTS: Of the 224 patients with PCC, 52 had IP-PCC (23.2 %), and 172 had non-IP-PCC (76.8 %). One hundred one of the 172 non-IP-PCC patients had a curative resection (curative resection rate 58.7 %). The follow-up duration ranged from 1.1 to 193.1 months (median 13.4 months). Overall survival (OS) rates for the non-IP-PCC patients at 1 and 5 years were 58.4 and 15.1 %, respectively. Absence of symptoms, lower alkaline phosphatase levels, normal carcinoembryonic antigen (CEA), and presence of MF-type PCC independently and favorably affected OS for the non-IP-PCC patients following hepatectomy. Independent factors favorably predicting OS for the MF-PCC patients were the absence of symptoms, hepatolithiasis, normal CEA levels, successful curative hepatectomy, and negative lymph node metastasis, while for the MF-PI-PCC patients following hepatectomy, one independent factor, successful curative hepatectomy, favorably predicted OS. For the PI-PCC patients, the independent factors favorably predicting OS were normal albumin levels and negative lymph node metastasis.
CONCLUSIONS: It is important to correctly differentiate between the gross pathological classifications of non-IP-PCC because of their distinct characteristics and outcomes following hepatectomy. Correct gross pathological classification is essential for further translational investigations.

Entities:  

Mesh:

Year:  2012        PMID: 23001251     DOI: 10.1007/s00535-012-0666-0

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  35 in total

1.  Surgical treatment of intrahepatic cholangiocarcinoma: four patients surviving more than five years.

Authors:  J Yamamoto; T Kosuge; T Takayama; K Shimada; M Makuuchi; J Yoshida; M Sakamoto; S Hirohashi; S Yamasaki; H Hasegawa
Journal:  Surgery       Date:  1992-06       Impact factor: 3.982

Review 2.  Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment.

Authors:  M F Chen
Journal:  J Gastroenterol Hepatol       Date:  1999-12       Impact factor: 4.029

3.  The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.

Authors:  A H Patel; D M Harnois; G G Klee; N F LaRusso; G J Gores
Journal:  Am J Gastroenterol       Date:  2000-01       Impact factor: 10.864

4.  Primary Carcinoma of the Liver: Cholangioma in Hepatolithiasis.

Authors:  S Sanes; J D Maccallum
Journal:  Am J Pathol       Date:  1942-07       Impact factor: 4.307

5.  Predictive factors for long-term survival in patients with intrahepatic cholangiocarcinoma.

Authors:  T Isa; T Kusano; H Shimoji; Y Takeshima; Y Muto; M Furukawa
Journal:  Am J Surg       Date:  2001-06       Impact factor: 2.565

6.  Report of the 16th follow-up survey of primary liver cancer.

Authors:  Iwao Ikai; Shigeki Arii; Takafumi Ichida; Kiwamu Okita; Masao Omata; Masamichi Kojiro; Kenichi Takayasu; Yasuni Nakanuma; Masatoshi Makuuchi; Yutaka Matsuyama; Yoshio Yamaoka
Journal:  Hepatol Res       Date:  2005-07-18       Impact factor: 4.288

7.  Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection.

Authors:  Alfredo Guglielmi; Andrea Ruzzenente; Tommaso Campagnaro; Silvia Pachera; Alessandro Valdegamberi; Paola Nicoli; Alessandro Cappellani; Giulio Malfermoni; Calogero Iacono
Journal:  World J Surg       Date:  2009-06       Impact factor: 3.352

8.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

9.  Mucosal dysplasia of the liver and the intraductal variant of peripheral cholangiocarcinoma in hepatolithiasis.

Authors:  T Ohta; T Nagakawa; N Ueda; T Nakamura; T Akiyama; K Ueno; I Miyazaki
Journal:  Cancer       Date:  1991-11-15       Impact factor: 6.860

10.  Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma.

Authors:  Shohachi Suzuki; Takanori Sakaguchi; Yoshihiro Yokoi; Kazuya Okamoto; Kiyotaka Kurachi; Yasuo Tsuchiya; Takuya Okumura; Hiroyuki Konno; Satoshi Baba; Satoshi Nakamura
Journal:  World J Surg       Date:  2002-03-26       Impact factor: 3.352

View more
  3 in total

1.  Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients.

Authors:  Chun-Yi Tsai; Shang-Yu Wang; Kun-Ming Chan; Wei-Chen Lee; Tse-Ching Chen; Ta-Sen Yeh; Yi-Yin Jan; Chun-Nan Yeh
Journal:  J Pers Med       Date:  2022-03-29

Review 2.  The Role of Surgical Resection and Liver Transplantation for the Treatment of Intrahepatic Cholangiocarcinoma.

Authors:  Guergana Panayotova; Jarot Guerra; James V Guarrera; Keri E Lunsford
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241

3.  Tumoral LINE-1 hypomethylation is associated with poor survival of patients with intrahepatic cholangiocarcinoma.

Authors:  Seorin Jeong; Kyoungbun Lee; Xianyu Wen; Younghoon Kim; Nam-Yun Cho; Ja-June Jang; Gyeong Hoon Kang
Journal:  BMC Cancer       Date:  2017-08-29       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.